EGFR and esophageal squamous cell carcinoma: A recent study showed that nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody that binds to the extracellular domain of the EGFR and inhibits epidermal growth factors binding, increases ESCC radiosensitivity dependent on the upregulation of IGFBP-317.